CREMECOMTRSBI (Germany) Performance
| WY52 Stock | EUR 0.05 0.02 68.75% |
The firm shows a Beta (market volatility) of -3.39, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning CREMECOMTRSBI are expected to decrease by larger amounts. On the other hand, during market turmoil, CREMECOMTRSBI is expected to outperform it. At this point, CREMECOMTRSBI DL 001 has a negative expected return of -1.39%. Please make sure to confirm CREMECOMTRSBI's treynor ratio, value at risk, and the relationship between the total risk alpha and maximum drawdown , to decide if CREMECOMTRSBI DL 001 performance from the past will be repeated in the future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days CREMECOMTRSBI DL 001 has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
CREMECOMTRSBI |
CREMECOMTRSBI Relative Risk vs. Return Landscape
If you would invest 163.00 in CREMECOMTRSBI DL 001 on September 4, 2024 and sell it today you would lose (157.60) from holding CREMECOMTRSBI DL 001 or give up 96.69% of portfolio value over 90 days. CREMECOMTRSBI DL 001 is producing return of less than zero assuming 28.0211% volatility of returns over the 90 days investment horizon. Simply put, majority of traded equity instruments are less risky than CREMECOMTRSBI on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
CREMECOMTRSBI Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CREMECOMTRSBI's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CREMECOMTRSBI DL 001, and traders can use it to determine the average amount a CREMECOMTRSBI's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0495
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | WY52 |
Estimated Market Risk
| 28.02 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.39 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average CREMECOMTRSBI is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CREMECOMTRSBI by adding CREMECOMTRSBI to a well-diversified portfolio.
CREMECOMTRSBI Fundamentals Growth
CREMECOMTRSBI Stock prices reflect investors' perceptions of the future prospects and financial health of CREMECOMTRSBI, and CREMECOMTRSBI fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CREMECOMTRSBI Stock performance.
| Return On Equity | 0.014 | |||
| Return On Asset | 0.0151 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.16 % | |||
| Shares Outstanding | 22.74 M | |||
| Price To Earning | 4.83 X | |||
| Revenue | 101.34 M | |||
| EBITDA | 36.01 M | |||
| Cash And Equivalents | 59.73 M | |||
| Cash Per Share | 2.56 X | |||
| Total Debt | 260.72 M | |||
| Debt To Equity | 0.64 % | |||
| Book Value Per Share | 1.71 X | |||
| Cash Flow From Operations | 25.43 M | |||
| Earnings Per Share | (0.65) X | |||
About CREMECOMTRSBI Performance
By analyzing CREMECOMTRSBI's fundamental ratios, stakeholders can gain valuable insights into CREMECOMTRSBI's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CREMECOMTRSBI has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CREMECOMTRSBI has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
CIM Commercial is a real estate investment trust that primarily acquires, owns, and operates Class A and creative office assets in vibrant and improving metropolitan communities throughout the United States . CIM Commercial is operated by affiliates of CIM Group, L.P., a vertically-integrated owner and operator of real assets with multi-disciplinary expertise and in-house research, acquisition, credit analysis, development, finance, leasing, and onsite property management capabilities. CIM COMM operates under REITOffice classification in Germany and is traded on Frankfurt Stock Exchange. It employs 4 people.Things to note about CREMECOMTRSBI DL 001 performance evaluation
Checking the ongoing alerts about CREMECOMTRSBI for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CREMECOMTRSBI DL 001 help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CREMECOMTRSBI DL 001 generated a negative expected return over the last 90 days | |
| CREMECOMTRSBI DL 001 has high historical volatility and very poor performance | |
| CREMECOMTRSBI DL 001 has some characteristics of a very speculative penny stock | |
| CREMECOMTRSBI DL 001 has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 101.34 M. Net Loss for the year was (30.95 M) with profit before overhead, payroll, taxes, and interest of 42.62 M. | |
| About 59.0% of the company outstanding shares are owned by institutional investors |
- Analyzing CREMECOMTRSBI's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CREMECOMTRSBI's stock is overvalued or undervalued compared to its peers.
- Examining CREMECOMTRSBI's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CREMECOMTRSBI's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CREMECOMTRSBI's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CREMECOMTRSBI's stock. These opinions can provide insight into CREMECOMTRSBI's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CREMECOMTRSBI Stock analysis
When running CREMECOMTRSBI's price analysis, check to measure CREMECOMTRSBI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CREMECOMTRSBI is operating at the current time. Most of CREMECOMTRSBI's value examination focuses on studying past and present price action to predict the probability of CREMECOMTRSBI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CREMECOMTRSBI's price. Additionally, you may evaluate how the addition of CREMECOMTRSBI to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |